Omeros (OMER) Notes Payables (2010 - 2012)

Omeros' (OMER) quarterly Notes Payables came in at $6.4 million in Q3 2012, up 20.82% year-on-year from $5.3 million in Q4 2011, and up 2.62% quarter-over-quarter from $6.2 million in Q2 2012.

Omeros (OMER) Notes Payables (2010 - 2012) Analysis & Trends

Omeros has disclosed Notes Payables across 3 years of filings, most recently posting $6.4 million for Q3 2012.

  • Notes Payables for Q3 2012 came in at $6.4 million, up 20.82% year-over-year; the trailing twelve-month figure through Sep 2012 was $6.4 million (up 20.82% YoY), and the FY2011 annual result was $5.9 million, up 1392.41% from the prior year.
  • Notes Payables came in at $6.4 million for Q3 2012 at Omeros, up from $6.2 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $6.4 million in Q3 2012 to a low of $395000.0 in Q4 2010.
  • The 3-year median for Notes Payables is $5.9 million (2011), against an average of $4.8 million.
  • Across the five-year window, Notes Payables soared 1392.41% in 2011 and advanced 20.82% in 2012, its largest moves.
  • Omeros' Notes Payables stood at $395000.0 in 2010, then jumped by 1392.41% to $5.9 million in 2011, then climbed by 8.11% to $6.4 million in 2012.
  • The last three Notes Payables figures came in at $6.4 million (Q3 2012), $6.2 million (Q2 2012), and $6.0 million (Q1 2012), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn -
7 Psyence Biomedical 212.16 Bn 212.16 Bn -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn
9 Abivax 91.96 Bn 91.96 Bn -
10 Omeros 737.87 Mn 602.55 Mn 9.31 Mn

Historic Data

Download Data
DateValue
Sep 30, 2012 6.37 Mn
Jun 30, 2012 6.21 Mn
Mar 31, 2012 6.05 Mn
Dec 31, 2011 5.90 Mn
Sep 30, 2011 5.28 Mn
Jun 30, 2011 3.72 Mn
Dec 31, 2010 395,000.00